Efficacy and Safety Evaluation of Febuxostat in the Treatment of Gouty Arthritis

OBJECTIVE To evaluate the efficacy and safety of etocoxib with febuxostat the treatment of gout arthritis. METHODS One hundred and ninety-seven patients with acute gout arthritis were randomly divided into three groups. Treated with etocoxib with febuostat (40 mg qd) to the group A, etocoxib with febuostat (80 mg qd) to the group B, and etocoxib with allopurinol 100 mg tid to the group C. After 1, 3, 7 and 13 weeks of treatment, observed the levels of joint pain, joint swelling and joint limitation, serum uric acid level and adverse drug reactions. RESULTS After 13 weeks, the effective rates of the three groups were 96.23%, 100% and 96.23%. At 3 weeks, group A had the best effect of lowering uric acid, and at 7 weeks and 13 weeks, group B and group C had a good effect of lowering uric acid. Group B had the smallest incidence of adverse drug reactions. CONCLUSION Etocoxib and febuostat (80 mg qd) have a good effect with little side effects in the treatment of gouty arthritis.